UK-CAB 71: Broadly Neutralising Antibodies (bNABs), POPPY Sleep study feedback

Friday 24 January 2020


09.15-09.25 Arrival, tea and refreshments
09:30-10:00 Welcome and introductions
UK-CAB updates
Company pre-meeting
10:00-11:30 Company meeting: ViiV Healthcare
11.30-11.40 Break
11.40-12.40 bNAbs – Simon Collins, HIV i-Base
12.45-14.00 Lunch
14.00-16.00 POPPY Sleep study community feedback – Alan Winston and Caroline Sabin
16.00-16:10 Break
16:10 -16.40 Conferences feedback – BHIVA, EACS
16.40-17.00 Members Updates
Meeting reflection
Any other business & reflection
17.00 Meeting close

Slides and meeting report

To be uploaded after the meeting.

Background reading and videos/webcasts – to follow

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.

This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

This entry was posted in Meetings. Bookmark the permalink. Comments are closed, but you can leave a trackback: Trackback URL.